|
Symbol
|
RMBWZV | RMAMHV | RMA0EV | OKYRCH | AAGITQ | OPJRCH | CDKBKB | KYOTDU | OSLRCH | RMAJ7V | OZARCH | OWRRCH | ABCVTQ | RMA6QV | KYXXDU | ABICTQ | RMBQ5V | KZEHDU | PELRCH | ABRBTQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Callable Multi Defender Vonti | Callable Multi Defender Vonti | Callable Multi Defender Vonti | Worst of Reverse Convertible | Callable Multi Barrier Reverse Convertible | Worst of Reverse Convertible | Barrier Reverse Convertible | Callable Multi Barrier Reverse Convertible | Worst of Reverse Convertible | Callable Multi Defender Vonti | Worst of Reverse Convertible | Worst of Reverse Convertible | Callable Multi Barrier Reverse Convertible | Callable Multi Defender Vonti | Callable Multi Barrier Reverse Convertible | Callable Multi Barrier Reverse Convertible | Callable Multi Defender Vonti | Autocallable Multi Barrier Reverse Convertible | Worst of Reverse Convertible | Callable Multi Barrier Reverse Convertible |
|
Underlying
|
Novartis AG / Novo Nordisk AS (B) / Sandoz Group AG | Eli Lilly & Co. / Novartis AG / Novo Nordisk AS (B) / Pfizer Inc. | Novo Nordisk AS (B) / Ypsomed Hldg. AG | Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly & Co. / Novo Nordisk AS (B) / Sanofi S.A. | ASML Hldg. N.V. / Novo Nordisk AS (B) / UniCredit S.p.A. | Eli Lilly & Co. / Novo Nordisk AS (B) / Roche AG | ASML Hldg. N.V. / Novo Nordisk AS (B) / Sanofi S.A. | Eli Lilly & Co. / Novo Nordisk AS (B) | Bachem Hldg. AG / Novo Nordisk AS (B) / Tecan Group AG | ASML Hldg. N.V. / Novo Nordisk AS (B) / SAP SE | Eli Lilly & Co. / Merck & Co. Inc. / Novo Nordisk AS (B) | Eli Lilly & Co. / Novo Nordisk AS (B) / Roche AG | Eli Lilly & Co. / Novartis AG / Novo Nordisk AS (B) / Roche AG | Eli Lilly & Co. / Merck & Co. Inc. / Novo Nordisk AS (B) | Eli Lilly & Co. / Lonza Group N / Novo Nordisk AS (B) | Eli Lilly & Co. / Novo Nordisk AS (B) / Roche AG / Ypsomed Hldg. AG | Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly & Co. / Lonza Group N / Novo Nordisk AS (B) |
|
Issuer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date of maturity
|
16.03.2026 | 02.03.2026 | 15.06.2026 | 24.12.2025 | 12.01.2026 | 26.01.2026 | 26.02.2026 | 16.02.2026 | 19.08.2026 | 20.03.2026 | 07.04.2026 | 20.03.2026 | 07.01.2026 | 27.03.2026 | 09.04.2026 | 05.05.2026 | 17.11.2026 | 20.11.2026 | 08.05.2026 | 10.06.2026 |
| Bid | 43.900 | 37.100 | - | - | 33.630 | - | 36.360 | 38.600 | 38.720 | 36.400 | 43.480 | - | 42.170 | 39.800 | 52.00 | 45.160 | - | 57.90 | 44.270 | 44.010 |
| Ask | - | - | - | - | - | - | - | 39.600 | - | - | - | - | - | - | 53.00 | - | - | 58.90 | - | - |